Luo Mian-Na, Yin Yanqing, Li Shangmei, Hao Junfeng, Yao Cuiwei, Xu Yong-Zhi, Liu Hua-Feng, Yang Lawei
Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Non-communicable Diseases, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Department of Nephrology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Front Pharmacol. 2023 Apr 7;14:1148553. doi: 10.3389/fphar.2023.1148553. eCollection 2023.
The present study aimed to prove the progression of immunoglobulin A nephropathy (IgAN) patients with isolated hematuria based on repeat renal biopsy data for the first time. 29 IgAN patients with isolated hematuria who received repeat renal biopsies were analyzed retrospectively, while 29 non-isolated hematuria IgAN patients with similar age and background were randomly selected as the control group. Clinical parameters were collected at the time of biopsy. The treatment strategies (conservative treatment with RASS blocker or immunosuppressive treatment) were choosen according to the pathological results at the first renal biopsy. The activity and chronicity indexes of renal lesions were evaluated. Markers of cell inflammation and proliferation were tseted by immunochemistry. The ultrastructure of podocytes was observed by transmission electron microscopy (TEM). Podocyte and oxidative stress marker (NPHS2 and 4-HNE) were detected by immunofluorescence. The IgAN patients with isolated hematuria had better clinical indicators than those with no-isolated hematuria, such as better renal function, higher albumin and lower uric acid. The interval between two biopsies in IgAN patients with isolated hematuria was 630 (interquartile range, 409.5-1,171) days. The hematuria of the patients decreased significantly from 30 (IQR, 4.00-35.00) RBC/ul in the first biopsy to 11 (IQR, 2.50-30.00) RBC/ul in the repeated biopsy ( < 0.05). The level of triglyceride decreased significantly ( < 0.05). The other clinical indicators were not statistically significant ( > 0.05). Deposits of IgA and C3 in the glomerulus were persistent. The activity index decreased, especially cellular crescent formation, while the chronicity index increased. The ultrastructure of podocytes was improved after treatment. The oxidative stress products of podocytes reduced after treatment. Although the clinical indicators of the IgAN patients with isolated hematuria were in the normal range, various acute and chronic pathological changes have occurred, and irreversible chronic changes have been progressing. Cell inflammation and proliferation persisted. Oxidative stress of podocytes was likely to be the therapeutic target. This study provided a strong basis for the progress of IgAN with isolated hematuria through pathological changes before and after treatment. This study will help clinicians recognize the harm of hematuria, change the traditional treatment concept, and help such patients get early treatment.
本研究旨在首次根据重复肾活检数据证实孤立性血尿的免疫球蛋白A肾病(IgAN)患者的病情进展。回顾性分析了29例接受重复肾活检的孤立性血尿IgAN患者,同时随机选取29例年龄和背景相似的非孤立性血尿IgAN患者作为对照组。在活检时收集临床参数。根据首次肾活检的病理结果选择治疗策略(使用RASS阻滞剂进行保守治疗或免疫抑制治疗)。评估肾损伤的活动度和慢性化指标。通过免疫化学检测细胞炎症和增殖标志物。通过透射电子显微镜(TEM)观察足细胞的超微结构。通过免疫荧光检测足细胞和氧化应激标志物(NPHS2和4-HNE)。孤立性血尿的IgAN患者的临床指标优于非孤立性血尿患者,如肾功能更好、白蛋白更高、尿酸更低。孤立性血尿IgAN患者两次活检之间的间隔为630(四分位间距,409.5 - 1171)天。患者的血尿从首次活检时的30(四分位间距,4.00 - 35.0)个红细胞/微升显著降至重复活检时的11(四分位间距,2.50 - 30.0)个红细胞/微升(P < 0.05)。甘油三酯水平显著下降(P < 0.05)。其他临床指标无统计学意义(P > 0.05)。肾小球中IgA和C3的沉积持续存在。活动度指标下降,尤其是细胞性新月体形成,而慢性化指标上升。治疗后足细胞的超微结构得到改善。治疗后足细胞的氧化应激产物减少。虽然孤立性血尿的IgAN患者的临床指标在正常范围内,但已发生各种急性和慢性病理变化,且不可逆的慢性变化一直在进展。细胞炎症和增殖持续存在。足细胞的氧化应激可能是治疗靶点。本研究通过治疗前后的病理变化为孤立性血尿IgAN的病情进展提供了有力依据。本研究将有助于临床医生认识血尿的危害,改变传统治疗观念,并帮助此类患者尽早接受治疗。